JP2000509243A - パスツレラ・ヘモリチカ白血球毒素に対する免疫 - Google Patents
パスツレラ・ヘモリチカ白血球毒素に対する免疫Info
- Publication number
- JP2000509243A JP2000509243A JP9516925A JP51692597A JP2000509243A JP 2000509243 A JP2000509243 A JP 2000509243A JP 9516925 A JP9516925 A JP 9516925A JP 51692597 A JP51692597 A JP 51692597A JP 2000509243 A JP2000509243 A JP 2000509243A
- Authority
- JP
- Japan
- Prior art keywords
- lkt
- gene
- toxin
- microorganism
- post
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003053 toxin Substances 0.000 title claims abstract description 106
- 231100000765 toxin Toxicity 0.000 title claims abstract description 105
- 241001293418 Mannheimia haemolytica Species 0.000 title claims description 35
- 210000000265 leukocyte Anatomy 0.000 title abstract description 8
- 230000036039 immunity Effects 0.000 title description 7
- 101710170970 Leukotoxin Proteins 0.000 claims abstract description 217
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 128
- 108700012359 toxins Proteins 0.000 claims abstract description 104
- 244000005700 microbiome Species 0.000 claims abstract description 96
- 239000012190 activator Substances 0.000 claims abstract description 29
- 239000002243 precursor Substances 0.000 claims abstract description 26
- 241001465754 Metazoa Species 0.000 claims abstract description 24
- 230000001323 posttranslational effect Effects 0.000 claims abstract description 21
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 238000013519 translation Methods 0.000 claims abstract description 10
- 230000002588 toxic effect Effects 0.000 claims abstract description 4
- 230000014509 gene expression Effects 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 36
- 239000013612 plasmid Substances 0.000 claims description 33
- 229960005486 vaccine Drugs 0.000 claims description 32
- 101150111062 C gene Proteins 0.000 claims description 22
- 239000013604 expression vector Substances 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000002255 vaccination Methods 0.000 claims description 15
- 241000606860 Pasteurella Species 0.000 claims description 14
- 210000000349 chromosome Anatomy 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 230000002759 chromosomal effect Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 244000052769 pathogen Species 0.000 claims description 10
- 238000002703 mutagenesis Methods 0.000 claims description 8
- 231100000350 mutagenesis Toxicity 0.000 claims description 8
- 238000007792 addition Methods 0.000 claims description 7
- 238000010367 cloning Methods 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 6
- 230000006798 recombination Effects 0.000 claims description 6
- 238000005215 recombination Methods 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 241000606750 Actinobacillus Species 0.000 claims description 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims description 4
- 101150097493 D gene Proteins 0.000 claims description 4
- 108020004511 Recombinant DNA Proteins 0.000 claims description 4
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 238000002741 site-directed mutagenesis Methods 0.000 claims description 4
- 241000588832 Bordetella pertussis Species 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 241000588772 Morganella morganii Species 0.000 claims description 3
- 241000588767 Proteus vulgaris Species 0.000 claims description 3
- 229940076266 morganella morganii Drugs 0.000 claims description 3
- 229940007042 proteus vulgaris Drugs 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 241000589902 Leptospira Species 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 241000702670 Rotavirus Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- 238000012224 gene deletion Methods 0.000 claims 2
- 238000012259 partial gene deletion Methods 0.000 claims 2
- 241000238557 Decapoda Species 0.000 claims 1
- 241001183197 Fusobacteriales Species 0.000 claims 1
- 241000606790 Haemophilus Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 244000052613 viral pathogen Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 abstract description 28
- 210000004072 lung Anatomy 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 206010035664 Pneumonia Diseases 0.000 abstract description 6
- 208000023504 respiratory system disease Diseases 0.000 abstract description 4
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical class C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract description 3
- 230000007123 defense Effects 0.000 abstract description 3
- 231100000776 exotoxin Toxicity 0.000 abstract description 3
- 239000002095 exotoxin Substances 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 206010037660 Pyrexia Diseases 0.000 abstract description 2
- 208000036142 Viral infection Diseases 0.000 abstract description 2
- 230000009089 cytolysis Effects 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000009385 viral infection Effects 0.000 abstract description 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 19
- 230000003902 lesion Effects 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000003550 marker Substances 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 229940031348 multivalent vaccine Drugs 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 101150055766 cat gene Proteins 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 101150000280 APX1 gene Proteins 0.000 description 3
- 101710112752 Cytotoxin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000002619 cytotoxin Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical group C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- -1 amino acid ester Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960001212 bacterial vaccine Drugs 0.000 description 2
- 239000007621 bhi medium Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- LYFYWXLKKQIOKO-UHFFFAOYSA-N 3,3-diaminopentan-1-ol Chemical compound CCC(N)(N)CCO LYFYWXLKKQIOKO-UHFFFAOYSA-N 0.000 description 1
- 102100040302 39S ribosomal protein L41, mitochondrial Human genes 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 101100493820 Caenorhabditis elegans best-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000701988 Escherichia virus T5 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 101150066516 GST gene Proteins 0.000 description 1
- 241001669573 Galeorhinus galeus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101001104225 Homo sapiens 39S ribosomal protein L41, mitochondrial Proteins 0.000 description 1
- 101000713813 Homo sapiens Quinone oxidoreductase PIG3 Proteins 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 101150095244 ac gene Proteins 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 244000079386 endoparasite Species 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical group [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229940022007 naked DNA vaccine Drugs 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.部分的にまたは完全に不活性化されているLkt毒素を産生する修飾微生 物。 2.該微生物のLkt構造遺伝子および/または翻訳後アクチベーターを含む Lkt毒素オペロンが部分的にまたは完全に不活性化されている、請求の範囲第 1項に記載の修飾微生物。 3.部分的にまたは完全に不活性化されているLkt毒素がLkt毒素前駆体 である、請求の範囲第1項または第2項に記載の修飾微生物。 4.部分的にまたは完全に不活性化されているLkt毒素がLkt構造遺伝子 のプロセッシングされない発現産物である、請求の範囲第2項または第3項に記 載の修飾微生物。 5.構造遺伝子がLkt A遺伝子である、請求の範囲第4項に記載の修飾微 生物。 6.翻訳後アクチベーターが部分的にまたは完全に欠失している、請求の範囲 第2項ないし第5項のいずれか1項に記載の修飾微生物。 7.翻訳後アクチベーターがLkt C遺伝子産物である、請求の範囲第2項 ないし第6項のいずれか1項に記載の修飾微生物。 8.翻訳後アクチベーターおよび/または構造遺伝子が、単一または複数のヌ クレオチド置換、付加および/または遺伝子の完全または部分欠失を含む欠失を 含む、翻訳後アクチベーターおよび/または構造遺伝子をコードする遺伝子由来 のDNAの導入および欠失を含む組換えDNA技術、標的構築物またはプラスミ ド分離を用いる相同的組換え、および化学的にまたは放射能により引き起こす突 然変異誘発または部位特異的突然変異誘発により、部分的にまたは完全に不活性 化されている、請求の範囲第2項ないし第7項のいずれか1項に記載の修飾微生 物。 9.微生物が、天然にLkt毒素を産生する生物体である、請求の範囲第1項 ないし第8項のいすれか1項に記載の修飾微生物。 10.微生物が、天然にはLkt毒素を産生しない生物体であるが、部分的にま たは完全に不活性化されたLkt毒素遺伝子が導入されているものである、請求 の範 囲第1項ないし第8項のいずれか1項に記載の修飾微生物。 11.アクチノバシラス種、プロテウス・ブルガリス、モルガネラ・モルガニイ 、ボルデテラ・ペルツシス、エシェリシア・コリ、パスツレラ種を含む群から選 択される、請求の範囲第1項ないし第10項のいずれか1項に記載の修飾微生物 。 12.微生物がパスツレラ種である、請求の範囲第11項に記載の修飾微生物。 13.パスツレラ種がパスツレラ・ヘモリチカである、請求の範囲第12項に記 載の修飾微生物。 14.微生物が、Lkt毒素遺伝子産物の分泌にかかわる少なくとも1種のタン パク質を産生できないものである、請求の範囲第1項ないし第13項のいずれか 1項に記載の修飾微生物。 15.微生物が、部分的にまたは完全に不活性されたLkt Bおよび/または 部分的にまたは完全に不活性化されたLkt D遺伝子を持つものである、請求 の範囲第14項に記載の修飾微生物。 16.部分的にまたは完全に不活性化されているLkt毒素をコードする発現ベ クターであって、該ベクターがLkt構造および/または翻訳後アクチベーター 遺伝子を含むLkt毒素遺伝子をコードしており、該Lkt毒素オペロンが完全 にまたは部分的に不活性化されているものである、ベクター。 17.Lkt毒素オペロンが、Lkt毒素前駆体をコードするものである、請求 の範囲第16項に記載の発現ベクター。 18.Lkt毒素遺伝子が、Lkt構造遺伝子のプロセッシングされない発現産 物の前駆体をコードするものである、請求の範囲第16項または第17項に記載 の発現ベクター。 19.構造遺伝子がLkt A遺伝子である、請求の範囲第18項に記載の発現 ベクター。 20.翻訳後アクチベーターが部分的にまたは完全に欠失している、請求の範囲 第16項ないし第19項のいずれか1項に記載の発現ベクター。 21.翻訳後アクチベーターがLkt C遺伝子である、請求の範囲第16項な いし第19項のいずれか1項に記載の発現ベクター。 22.翻訳後アクチベーターおよび/または構造遺伝子が、単一または複数のヌ クレオチド置換、付加および/または遺伝子の完全または部分欠失を含む欠失を 含む、翻訳後アクチベーターおよび/または構造遺伝子をコードする遺伝子由来 のDNAの導入および欠失を含む組換えDNA技術、標的構築物またはプラスミ ド分離を用いる相同的組換え、および化学的にまたは放射能により引き起こす然 変異誘発または部位特異的突然変異誘発により、部分的にまたは完全に不活性化 されている、請求の範囲第16項ないし第21項のいずれか1項に記載の発現ベ クター。 23.天然にLkt毒素を産生する微生物に由来する染色体または染色体外エレ メントである、請求の範囲第16項ないし第22項のいずれか1項に記載の発現 ベクター。 24.該染色体または染色体外エレメントがプラスミドである、請求の範囲第2 3項に記載の発現ベクター。 25.アクチノバシラス種、プロテウス・ブルガリス、モルガネラ・モルガニイ 、ボルデテラ・ペルツシス、エシェリシア・コリおよびパスツレラ種を含む群か ら選択される微生物に由来する、請求の範囲第23項または第24項に記載の発 現ベクター。 26.パスツレラ由来のプラスミドベクターである、請求の範囲第24項または 第25項に記載の発現ベクター。 27.パスツレラ・ヘモリチカ由来のプラスミドベクターである、請求の範囲第 26項に記載の発現ベクター。 28.更に、E.コリへのDNA導入を容易にする、マルチクローニングサイト 、lac遺伝子またはその部分の少なくとも1つを含むヌクレオチド配列を含む、 請求の範囲第16項ないし第27項のいずれか1項に記載の発現ベクター。 29.請求の範囲第16項ないし第28項のいずれか1項に記載の発現ベクター によりコードされるLkt毒素オペロン産物。 30.請求の範囲第29項に記載のLkt毒素遺伝子産物を含む、宿主動物にお いてLkt毒素に対する免疫学的応答を誘発するためのワクチン組成物。 31.部分的にまたは完全に不活性化されているLkt毒素を産生する修飾微生 物を含む、宿主動物においてLkt毒素に対する免疫学的応答を誘発するための ワクチン組成物。 32.請求の範囲第1項ないし第15項のいずれか1項に記載の修飾微生物を含 む、請求の範囲第30項に記載のワクチン組成物。 33.対応するLkt毒素を産生するある範囲の血清型の微生物に対する免疫応 答を誘発するための、請求の範囲第31項ないし第32項のいずれか1項に記載 のワクチン組成物。 34.Lkt毒素がパスツレラ種から産生される毒素である、請求の範囲第33 項に記載のワクチン組成物。 35.Lkt毒素がパスツレラ・ヘモリチカから産生される、請求の範囲第33 項または34項に記載のワクチン組成物。 36.請求の範囲第1項ないし第15項のいずれか1項に記載の修飾微生物を含 む生物ベクター。 37.更に、宿主細胞において応答を増強する能力のある生物学的に活性な分子 を提供する、請求の範囲第36項に記載の生物ベクター。 38.該生物学的に活性な分子が、成長因子、ホルモン、酵素、抗原またはその 抗原性部分、インターロイキンなどのサイトカイン、インターフェロンおよび腫 瘍壊死因子などの機能性分子含む群から選択される、請求の範囲第37項に記載 の生物ベクター。 39.該生物学的に活性な分子が、生物学的に活性な分子をコードする遺伝子を 持つプラスミドを伴う生物ベクターにより発現される、請求の範囲第37項また は第38項に記載の生物ベクター。 40.該微生物が、微生物に固有の2種以上の抗原エピトープに対する免疫応答 を誘発する能力がある、請求の範囲第36項ないし39項のいずれか1項に記載 の生物ベクター。 41.該免疫応答が、該微生物の有毒形態および該微生物により発現される異種 抗原に対して誘導される、請求の範囲第40項に記載の生物ベクター。 42.該免疫応答が、Lkt毒素と、パスツレラ種、ヘモフィラス種、モラキセ ラ種、レプトスピラ種、ストレプトコッカス種、サルモネラ種、E.コリ、フソ バクテリウム種、クロストリジウム種、マイコバクテリウム種を含む細菌病原体 ;ヘモカス種、トリコストロンジラス種を含む内部寄生体;ブーフィラス種を含 む外部寄生体;ウシウイルス性下痢ウイルス(BVDV)、パラインフルエンザウ イルス(PI3)、感染性ウシ鼻腔気管炎(IBR)、コロナウイルス、および ロタウイルスを含むウイルス病原体から選択される1種以上の病原体の少なくと も1つの抗原エビトープに対して誘導される、請求の範囲第40項または第41 項に記載の生物ベクター。 43.活性Lkt毒素を産生する微生物を提供すること;および、 Lkt構造遺伝子および/または翻訳後アクチベーターを部分的にまたは 完全に不活性化すること、 を含んでなる、部分的にまたは完全に不活性化されているLkt毒素を産生する 修飾微生物の製法。 44.該構造遺伝子がLkt A遺伝子である、請求の範囲第43項に記載の修 飾微生物の製法。 45.該翻訳後アクチベーター遺伝子がLkt C遺伝子である、請求の範囲第 43項または第44項に記載の修飾微生物の製法。 46.該構造遺伝子および/または該翻訳後アクチベーターが、単一または複数 のヌクレオチド置換、付加および/または遺伝子の完全または部分欠失を含む欠 失を含む、翻訳後アクチベーターおよび/または構造遺伝子をコードする遺伝子 由来のDNAの導入および欠失を含む組換えDNA技術、標的構築物またはプラ スミド分離を用いる相同的組換え、および化学的にまたは放射能により引き起こ す突然変異誘発または部位特異的突然変異誘発により、部分的にまたは完全に不 活性化されている、請求の範囲第43項ないし第45項のいずれか1項に記載の 方法。 47.請求の範囲第43項ないし第46項のいずれか1項に従い調製された修飾 微生物。 48.生物ベクターを提供すること、および 請求の範囲第16項ないし第28項のいずれか1項に記載の発現ベクター を該生物ベクターへ導入すること、 を含んでなる、部分的にまたは完全に不活性化されているLkt毒素を産生する 修飾微生物の製法。 49.請求の範囲第30項ないし第35項のいずれか1項に記載のワクチン組成 物の免疫学的有効量を動物に投与することを含む、Lkt毒素産生微生物に対す る動物のワクチン接種法。 50.請求の範囲第1項ないし第15項のいずれか1項に記載の修飾微生物を培養 し、該微生物によって産生された部分的にまたは完全に不活性な毒素を回収する ことを含む、不活性Lkt毒素の製法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU6313 | 1995-11-02 | ||
AUPN6313A AUPN631395A0 (en) | 1995-11-02 | 1995-11-02 | Vaccine and biological vector(II) |
PCT/AU1996/000685 WO1997016531A1 (en) | 1995-11-02 | 1996-11-01 | Immunity against pasteurella haemolytica leukotoxin |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000509243A true JP2000509243A (ja) | 2000-07-25 |
JP2000509243A5 JP2000509243A5 (ja) | 2004-09-16 |
JP3905127B2 JP3905127B2 (ja) | 2007-04-18 |
Family
ID=3790638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51692597A Expired - Lifetime JP3905127B2 (ja) | 1995-11-02 | 1996-11-01 | パスツレラ・ヘモリチカ白血球毒素に対する免疫 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6610307B1 (ja) |
EP (1) | EP0862615B1 (ja) |
JP (1) | JP3905127B2 (ja) |
AU (1) | AUPN631395A0 (ja) |
BR (2) | BR9611278A (ja) |
CA (1) | CA2236700C (ja) |
DE (1) | DE69631543T2 (ja) |
ES (1) | ES2211982T3 (ja) |
MX (1) | MX9803370A (ja) |
NZ (1) | NZ320025A (ja) |
WO (1) | WO1997016531A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840556A (en) | 1996-05-08 | 1998-11-24 | The United States Of America As Represented By The Department Of Agriculture | Molecular genetic construction of vaccine strains of pasteurellaceae |
US6770275B1 (en) * | 1996-05-31 | 2004-08-03 | Akzo Nobel N.V. | Live attenuated RTC-producing bacteria of the family |
NZ503463A (en) * | 1997-09-25 | 2002-10-25 | Biotechnology Res & Dev | Leukotoxin deletion mutant of Pasteurella haemolytica |
US6936262B2 (en) | 1997-09-25 | 2005-08-30 | Biotechnology Research And Development Corporation | LktA deletion mutant of P. haemolytica |
US8053406B2 (en) | 2005-11-25 | 2011-11-08 | University Of Medicine And Dentistry Of New Jersey | Compositions for the treatment of cancer, and methods for testing and using the same |
WO2007062150A2 (en) * | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Leukotoxin compositions and therapeutic methods |
US10149889B2 (en) | 2005-11-25 | 2018-12-11 | Rutgers, The State University Of New Jersey | Compositions for the treatment of cancer, and methods for testing and using the same |
US8926990B2 (en) | 2009-10-13 | 2015-01-06 | Rutgers, The State University Of New Jersey | Treatment and diagnosis of inflammatory disorders and HIV |
EP2916863B1 (en) | 2012-11-08 | 2018-05-30 | Merial, Inc. | Attenuated mannheimia haemolytica vaccines and methods of making and use |
US9814769B2 (en) | 2014-09-30 | 2017-11-14 | Qatar University | Vaccines against pathogenic Escherichia coli and methods of using the same |
NL2018155B1 (en) | 2017-01-11 | 2018-07-25 | Intervet Int Bv | Oral vaccine against ruminant respiratory disease |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963487A (en) * | 1985-01-03 | 1990-10-16 | Massachusetts Institute Of Technology | Method for deletion of a gene from a bacteria |
US5165924A (en) * | 1986-01-22 | 1992-11-24 | University Of Guelph | Serum-free, cell-free vaccine effective against pneumonic pasteurellosis in cattle |
US5885589A (en) * | 1988-04-12 | 1999-03-23 | Intervet International B.V. | Pasteurella vaccine |
GB8912330D0 (en) * | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
US5641653A (en) * | 1989-10-31 | 1997-06-24 | The Texas A&M University System | DNA encoding Actinobacillus pleuropneumoniae hemolysin |
CA2045950C (en) * | 1991-06-28 | 2004-05-11 | Elbarte M. Kamp | Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections |
US5422110A (en) * | 1991-10-16 | 1995-06-06 | University Of Saskatchewan | Enhanced immunogenicity using leukotoxin chimeras |
AUPN631495A0 (en) * | 1995-11-02 | 1995-11-23 | Commonwealth Scientific And Industrial Research Organisation | Vaccine and biological vector(I) |
AU6969798A (en) * | 1997-04-15 | 1998-11-11 | Baylor College Of Medicine | (pasteurella haemolytica) vaccine |
-
1995
- 1995-11-02 AU AUPN6313A patent/AUPN631395A0/en not_active Abandoned
-
1996
- 1996-11-01 JP JP51692597A patent/JP3905127B2/ja not_active Expired - Lifetime
- 1996-11-01 CA CA2236700A patent/CA2236700C/en not_active Expired - Lifetime
- 1996-11-01 DE DE69631543T patent/DE69631543T2/de not_active Expired - Lifetime
- 1996-11-01 WO PCT/AU1996/000685 patent/WO1997016531A1/en active IP Right Grant
- 1996-11-01 BR BR9611278A patent/BR9611278A/pt not_active IP Right Cessation
- 1996-11-01 EP EP96934209A patent/EP0862615B1/en not_active Expired - Lifetime
- 1996-11-01 ES ES96934209T patent/ES2211982T3/es not_active Expired - Lifetime
- 1996-11-01 BR BRPI9611278D patent/BR9611278B1/pt unknown
- 1996-11-01 US US09/068,100 patent/US6610307B1/en not_active Expired - Lifetime
- 1996-11-01 NZ NZ320025A patent/NZ320025A/en not_active IP Right Cessation
-
1998
- 1998-04-29 MX MX9803370A patent/MX9803370A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
DE69631543T2 (de) | 2004-09-16 |
CA2236700A1 (en) | 1997-05-09 |
EP0862615A4 (en) | 2000-01-12 |
EP0862615A1 (en) | 1998-09-09 |
WO1997016531A1 (en) | 1997-05-09 |
NZ320025A (en) | 1999-04-29 |
ES2211982T3 (es) | 2004-07-16 |
EP0862615B1 (en) | 2004-02-11 |
MX9803370A (es) | 1998-11-30 |
BR9611278B1 (pt) | 2016-05-24 |
AUPN631395A0 (en) | 1995-11-23 |
JP3905127B2 (ja) | 2007-04-18 |
DE69631543D1 (de) | 2004-03-18 |
CA2236700C (en) | 2010-06-29 |
US6610307B1 (en) | 2003-08-26 |
BR9611278A (pt) | 1999-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU745003B2 (en) | Live attenuated vaccines | |
US10603371B2 (en) | Attenuated Pasteurella multocida vaccines and methods of making and use thereof | |
JP3905128B2 (ja) | アクチノバシラス・プリゥロニュウモニエrtx毒素apxに対する免疫 | |
JP3905127B2 (ja) | パスツレラ・ヘモリチカ白血球毒素に対する免疫 | |
KR100510906B1 (ko) | 악티노 바실러스 플루로뉴모니아종의 약독화 생박테리아 | |
PT1017822E (pt) | Mutante de eliminação da lkta de p. haemolytica | |
US6783764B1 (en) | Actinobacillus pleuropneumoniae subunit vaccine | |
US6770275B1 (en) | Live attenuated RTC-producing bacteria of the family | |
MXPA97004061A (es) | Bacterias productoras de rtx atenuadas vivas de la familia pasteurellaceae | |
EP1518558B1 (en) | Vaccine against infection with Actinobacillus pleuropneumoniae comprising purified ApxIV toxin | |
AU717773B2 (en) | Immunity against pasteurella haemolytica leukotoxin | |
Pedersen et al. | 987P fimbriae from porcine enterotoxigenic Escherichia coli: characterization, N-terminal amino acid sequence and immunization with purified antigen | |
WO2018167485A1 (en) | Whole cell vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060720 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061012 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070111 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110119 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110119 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120119 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130119 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130119 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |